IgM myeloma and Waldenstrom's macroglobulinemia: A distinct clinical feature, histology, immunophenotype, and chromosomal abnormality

Clinical and Laboratory Haematology

Volumn 25, Issue 3, 2003, Pages 187-190

  Chehal, A ^a   Taher, A ^a   Shamseddine, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Macroglobulinemia; Myeloma

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN M; PAMIDRONIC ACID; THALIDOMIDE;

ADULT; ARTICLE; CASE REPORT; CHROMOSOME ABERRATION; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; MALE; MYELOMA; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

CHROMOSOME ABERRATIONS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 0038236941     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.2003.00511.x     Document Type: Article

References (23)

1. Bachman R. (1965) The diagnostic significance of the serum concentration of pathological proteins (M-components). Acta Medica Scandinavica 178, 801-808.
2. Bartl R., Frisch B. & Wilmans W. (1995) Morphology of multiple myeloma. In: Myeloma: Biology and Management. (eds. J.S. Malpas, D.E. Bergsagel & R.A. Kyle). pp. 82-123. Oxford University Press, New York.
3. Bergsagel D.E. (1990) Macroglobulinemia. In: Hematology. (eds. W.J. Williams, E. Beutler, A.J. Erslev & L. Lichtman), pp. 1141-1145. McGraw-Hill, New York.
4. Berman H.H. (1974) Waldenstrom's macroglobulinemia with lytic osseous lesions and plasma cell morphology: report of a case. American Journal of Clinical Pathology 63, 397-402.
5. Boccadoro M. & Pileri A. (1997) Diagnosis, prognosis and standard treatment of multiple myeloma. Hematology/Oncology clinics of North America 11, 111-127.
6. Calasanz M.J., Cigadosa J.C., Odero M.D., Ferreira C., Ardanaz M.T., Fraile A., Carrasco J.C., Sole F., Cuesta B. & Gullon A. (1997) Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary break points and clinical correlations. Genes Chromosomes Cancer 18, 84-93.
7. Callihan T.R., Holbert J.M. & Berard C.W. (1983) Neoplasms of terminal B-cell differentiation: the morphologic beloma and related disorders: primary break points and clinical correlationsasis of functional diversity. In: Malignant Lymphomas: A Pathology Annual Monograph. (eds. S. Sommers & P.P. Rosen), pp. 169-286. Appleton-Centuey-Crofts, Norwalk, CT.
8. De Cramont A., Crobois B., Michaux J.L., Peny A.M., Pollet J.P., Smadja N., Krulik M., Debray J., Bernard J.F. & Monconduit M. (1990) IgM myeloma: 6 cases and a review of the literature. Revue de Medecine Interne 11, 13-18.
9. Dierlamm T., Lack E., Dierlamm J., Fiedler W. & Hossfeld D.K. (2002) IgM myeloma: a report of four cases. Annals of Hematology 81, 136-139.
10. Dimopoulos A.D. & Alexanian R. (1994) Waldenstrom's macroglubulinemia. Blood 83, 1452-1459.
11. Fundenberg H.H. & Virella G. (1980) Multiple myeloma, and Waldenstrom's macroglubulinemia: unusual presentations. Seminars in Hematology 17, 63-79.
12. Haghighi B., Yanagihara R. & Cornbleet J. (1998) IgM myeloma: case report with immunophenotypic profile. American Journal of Hematology 59, 302-308.
13. Harousseua J.L., Attal M., Divine M., Marit C., Leblond V., Stoppa A.M., Bourhis J.H., Caillot D., Boasson M. & Abgrall J.F. (1995) Autologus stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologus transplantation in multiple myeloma. Blood 85, 3077-3085.
14. Hobbs J.R. (1968) A case of Waldenstrom's macroglubulinemia with slow progression (in clinicopathological conference). British Medical Journal 111, 237-242.
15. Lackner H. (1973) Hemostatic abnormalities associated with dysproteinemias. Seminar in Hematology 10, 125-133.
16. Maclennan I.C.M. (1992) In which cells does neoplastic transformation occurs in myelomatosis? Current Topics in Microbiology and Immunology 182, 209-213.
17. Mouloupoulos L.A., Dimopoulos M.A., Varma D.C.K., Manning J.T., Johnston D.A., Leeds N.E. & Libshitz H.I. (1993) Waldenstrom's macroglubulinemia: MR imaging of the spine and CT of the abodomen and pelvis. Radiology 188, 669-673.
18. Rajkumar S.V. (2001) Thalidomide in the treatment of multiple myeloma. Expert Review on Anticancer Therapy 1, 20-28.
19. Salmon S.E. (1974) Paraneoplastic syndromes associate with monoclonal lymphocyte and plasma cell proliferation. Annals of the New York Academy of Sciences 230, 228-239.
20. Takahashi K., Yamamura F. & Motoyama H. (1986) IgM myeloma: its distinction from Waldenstrom's macroglubulinemia. Acta Pathotogica Japonica 36, 1553-1563.
21. Waldenstrom J. (1965) Macroglubulinemia. Advancement in Metabolic Disorder 2, 116-158.
22. Wong K.F. (2003) Waldenstrom's macroglubulinemia with a novel der (8, 17) (q10, q10). Cancer Genetics and Cytogenetics 14, 83-85.
23. Zarrabi M., Stark R., Kane P., Dannaher C. & Chandor S. (1981) IgM myeloma, a distinct entity in the spectrum of B-cell neoplasia. American Journal of Clinical Pathology 75, 1-10.